Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1648 1671 1672
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17769940 | METHODS FOR ULTRASENSITIVE DETECTION OF PROTEIN AND CELLULAR BIOMARKERS | Non-Final OA | GEORGIA TECH RESEARCH CORPORATION |
| 17489273 | METHODS, DEVICES, AND RELATED ASPECTS FOR DETECTING EBOLA VIRUS | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18012143 | FLAVIVIRUS SIGNAL PEPTIDES, VACCINE CONSTRUCTS, AND METHODS THEREFOR | Non-Final OA | University of Connecticut |
| 17488384 | RAPID TEST SYSTEM FOR VIRAL AND BACTERIAL INFECTIONS | Non-Final OA | The Cleveland Clinic Foundation |
| 18574482 | UNIVERSAL VACCINE FOR INFLUENZA VIRUS BASED ON TETRAMERIC M2 PROTEIN INCORPORATED INTO NANODISCS | Non-Final OA | The Board of Trustees of the University of Illinois |
| 17395143 | CELL-BASED ASSAY FOR DETECTION OF ANTIBODIES IN A SAMPLE | Non-Final OA | Becton, Dickinson and Company |
| 17310245 | VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF | Final Rejection | Board of Regents of the University of Nebraska |
| 18988667 | ASSESSMENT AND TREATMENT OF CHRONIC HEPATITIS B | Non-Final OA | BRII BIOSCIENCES, INC. |
| 18264737 | ONCOLYTIC VIRUS FOR SYSTEMIC DELIVERY AND ENHANCED ANTI-TUMOR ACTIVITIES | Non-Final OA | UNIVERSITY OF HOUSTON SYSTEM |
| 17845502 | Methods and Systems for Detecting SARS-CoV-2 Analytes in Dried Samples | Final Rejection | Laboratory Corporation of America Holdings |
| 17612426 | DOSAGE REGIMENS FOR VACCINES | Non-Final OA | Gilead Sciences, Inc. |
| 17757599 | VIRUS-LIKE PARTICLE BINDING AGENTS, RELATED COMPOSITIONS, AND RELATED METHODS | Non-Final OA | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. |
| 18249419 | BACULOVIRUS EXPRESSION VECTOR | Non-Final OA | Intervet Inc. |
| 17441588 | VIRUS-LIKE PARTICLES AND USES THEREOF | Final Rejection | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. |
| 17309796 | ANTI-HEPATITIS C VIRUS ANTIBODIES | Non-Final OA | BAR ILAN UNIVERSITY |
| 17603774 | VIRAL VECTOR MANUFACTURING METHODS | Final Rejection | CHILDREN'S HOSPITAL MEDICAL CENTER |
| 18275226 | S-RBD Trimer Protein Vaccine for Novel Coronavirus and Preparation Method and Application Therefor | Non-Final OA | NATIONAL VACCINE AND SERUM INSTITUTE (NVSl) |
| 18257334 | ENTEROVIRUS PURIFICATION WITH CATION EXCHANGE CHROMATOGRAPHY | Non-Final OA | Andrew Ryan SWARTZ |
| 18254576 | MODIFIED HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN AND USE THEREOF | Non-Final OA | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences |
| 18012281 | BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) | Non-Final OA | Navigo Proteins GmbH |
| 17641059 | TRANSDUCTION EFFICIENCY ASSAY | Final Rejection | Genetix Biotherapeutics Inc. |
| 18026544 | CORONAVIRUS ANTIBODIES AND USES THEREOF | Non-Final OA | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES |
| 18041025 | CORONAVIRUS POINT-OF-CARE AGGLUTINATION ASSAY | Final Rejection | Veravas, Inc. |
| 18002844 | ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND USES THEREOF | Non-Final OA | HUMABS BIOMED SA |
| 17922520 | Detection of viruses in facemasks | Final Rejection | Camas Incorporated |
| 17896801 | METHOD OF DETECTING A RESPIRATORY VIRAL INFECTION | Final Rejection | Breathonix Pte. Ltd. |
| 17782899 | PROCESS FOR PRODUCING A PROPHYLACTIC AND THERAPEUTIC DNA IMMUNOLOGICAL COMPOSITION FOR HPV AND CANCERS ASSOCIATED WITH THE VIRUS, HYBRID PROTEIN, EXPRESSION VECTOR, IMMUNOLOGICAL COMPOSITION AND USES THEREOF | Non-Final OA | INSTITUTO BUTANTAN |
| 17623862 | Recombinant Human Papillomavirus Vaccine Composition and Use thereof | Non-Final OA | IMMUNE-PATH BIOTECHNOLOGY (SUZHOU) CO., LTD. |
| 17486823 | ONCOLYTIC MYXOMA VIRUS EXPRESSING FAST P14 TO TREAT HEMATOLOGICAL CANCER | Final Rejection | Roy Duncan |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy